Biogen Idec Inc BIIB:NASDAQ (Common Stock)

LastChange / % ChangeDividend YieldVolumeAvg Volume (10 day)
410.10 1.16   0.28%863,7821.0M
Market data is delayed by at least 20 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Market is closed. As of 04:00 PM ET 2/26/2015

Latest News Headlines for Biogen Idec Inc

Post-Earnings Coverage - Biogen Idec

LONDON, February 26, 2015 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Investor-Edge.com has issued free post-earnings coverage on Biogen Idec Inc. (NASDAQ: BIIB). On January 29, 2015, the company reported its financial results for Q4 FY14 and full year FY14 (period ended December 31, 2014). Click on http://get.Investor-Edge.com/pdf/?c=Biogen%20Idec&d=26-Feb-2015&s=BIIB to read our free earnings review on Biogen Idec Inc. (Biogen Idec). During Q4 FY14 and full-year FY14, the company's total revenues grew 34% Y-o-Y and 40% Y-o-Y, respectively. Additionally, GAAP net income attributable to Biogen Idec surged 93% Y-o-Y in Q4 FY14 and 58% Y-o-Y in FY14. Our free coverage report can be accessed at:

Biogen Idec to Present at the Cowen and Company 35(th) Annual Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--February 23, 2015-- Biogen Idec Inc. (NASDAQ: BIIB) announced today that it will present at the Cowen and Company 35(th) Annual Healthcare Conference. The webcast will be live on Monday, March 2, 2015 at 2:50 p.m. ET. To access the live webcast, please visit Biogen Idec's Investors section at www.biogenidec.com. An archived version of the webcast will be available for 14 days following the presentation.

Biogen Idec, Columbia University and HudsonAlpha Institute Identify New ALS Gene and Signaling Pathways

-- Findings Point to Potential Therapeutic Targets -- CAMBRIDGE, Mass. & NEW YORK & HUNTSVILLE, Ala.--(BUSINESS WIRE)--February 19, 2015-- Using advanced DNA sequencing methods, an international consortium that includes scientists and clinicians from Columbia University Medical Center (CUMC), Biogen Idec (NASDAQ: BIIB) and HudsonAlpha Institute for Biotechnology has identified a new gene that is associated with sporadic amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease. The newly associated gene, called TBK1 (TANK-Binding Kinase 1), plays a key role at the intersection of two essential cellular pathways: inflammation (a reaction to injury or infection) and autophagy (a cellular process involved in the removal of damaged cellular components). The study was published today in the online edition of Science.

View more recent headlines

Peers Information HelpBIIB Biogen Idec Inc vs. Peers

BIIB
Biogen Idec Inc
20.47%
-3.21%
Johnson & Johnson
Pfizer Inc.
11.27%
Merck & Co., Inc.
2.99%
-7.37%
AbbVie Inc
BIIB
Biogen Idec Inc
0.00%
Johnson & Johnson
2.72%
Pfizer Inc.
3.24%
Merck & Co., Inc.
3.05%
AbbVie Inc
3.37%
BIIB
Biogen Idec Inc
0.28%
Johnson & Johnson
1.57%
-0.20%
Pfizer Inc.
Merck & Co., Inc.
0.80%
-0.16%
AbbVie Inc
Compare these stocks

Latest Annual and Quarterly SEC Filings

More Filings
10-K

This report contains detailed information about the company's business finances and management.

10-Q

Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Biogen Idec Inc. is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company’s products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. AVONEX is prescribed treatments for relapsing forms of multiple sclerosis (MS). AVONEX is a recombinant form of the interferon beta protein produced in the body in response to viral infection. TYSABRI is a monoclonal antibody approved in numerous countries as a monotherapy treatment for relapsing MS and to treat Crohn’s disease. The Company’s RITUXAN is a monoclonal antibody therapeutic used to treat non-Hodgkin’s lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia among others. FAMPYRA addresses the need of walking improvement in adult patients with MS who have walking disability and for the treatment of psoriasis.

http://www.biogenidec.com/

Loading...

collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open408.82
Previous Close408.94
Day High411.77
Day Low406.065
52 Week High2/25/2015 | 412.02
52 Week Low4/15/2014 | 272.02
% Off 52 Week High-0.47%
% Off 52 Week Low50.76%
Beta (5 Yr)1.0
Volatility Avg2/26/2015 | 35.25
10-Day Avg. Volume1,037,320
Market data is delayed by at least 20 minutes.

collapse, right-facing arrow indicating collapsed view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)12/31/2014 | 12.38
P/E Ratio12/31/2014 | 33.0
Market CapLarge Cap | 96.2B
Shares Outstanding234.61M
Float234.4M

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield--
Ex-Date--
Dividend Announcement--
Date of Record--
Payable-- - --
Payable Date--

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short3.29M
Short Ratio1.9
Short % of Float1.40%
As of 2/15/2015